Opendata, web and dolomites

Ru4EYE SIGNED

Ruthenium-based photoactivated chemotherapy against eye cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Ru4EYE project word cloud

Explore the words cloud of the Ru4EYE project. It provides you a very rough idea of what is the project "Ru4EYE" about.

completion    group    photosensitive    accelerate    presentation    patients    oxygen    normoxic    start    hypoxic    mechanism    proof    melanoma    positive    cytotoxic    independent    difficult    eye    vitro    bioactive    poc    series    erc    translational    patient    performed    save    spheroids    capital    vision    liver    selectively    site    pact    first    death    grant    cells    starting    nature    treat    tumor    always    diseases    toxicity    models    zebrafish    activation    drug    efficacy    bond    market    light    rare    uveal    treatment    risky    driving    clinics    agents    translation    preserve    action    disease    metastasis    compounds    reaction    vivo    clinical    ruprolight    complete    evaluation    appealing    phototherapy    agent    venture    embryo    chemotherapy    irradiation    removable    relatively    3d    photochemical    kill    um    therapeutic    ru4eye    innovative    dioxygen    ru    exist    model    xenografts    2d    solutions    mouse    biological    monolayers    trials    photoactivated    cancer    form    appears    breakage    malignancy    solution    protecting   

Project "Ru4EYE" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT LEIDEN 

Organization address
address: RAPENBURG 70
city: LEIDEN
postcode: 2311 EZ
website: www.universiteitleiden.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2021-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT LEIDEN NL (LEIDEN) coordinator 150˙000.00

Map

 Project objective

The Ru4EYE PoC proposal will develop the first pre-clinical evaluation of Ru-based PACT compounds in uveal melanoma (UM) model. UM is a rare malignancy of the eye. Although treatment against UM do exist, they do no always preserve vision or the eye, and often lead to patient death via metastasis to the liver. A better treatment that would save vision, the eye, and the patient, is looked after. UM appears as an appealing disease for photoactivated chemotherapy (PACT), a new form of phototherapy developed within my ERC Starting Grant RuProLight. PACT agents are photosensitive compounds that can kill cancer cells selectively under the action of light. In PACT dioxygen does not need to be present at the site of light irradiation because the mechanism of photochemical activation is an oxygen-independent bond breakage reaction between a bioactive, cytotoxic agent, and a light-removable protecting group. Innovative therapeutic solutions such as PACT are typically difficult to bring to the market because of the risky nature of drug development and the funding required for clinical trials. The vision in this grant proposal is that positive results on a rare form of cancer such as uveal melanoma could not only offer a relatively short-term solution to uveal melanoma patients, but also accelerate translation of Ru-based PACT to the clinics by driving developments for other diseases as well. The biological testing of Ru-based PACT compounds will be performed in a complete series of translational cancer models: from in vitro (2D monolayers of normoxic and hypoxic cancer cells, 3D tumor spheroids) to in vivo (xenografts in zebrafish embryo for studying metastasis formation and treatment, and mouse model for in vivo toxicity and efficacy). The aim is to develop a pre-clinical proof-of-concept that PACT can be used to treat uveal melanoma, so that presentation to venture capital and clinical testing can start quickly after completion of the project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RU4EYE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RU4EYE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

HEIST (2020)

High-temperature Electrochemical Impedance Spectroscopy Transmission electron microscopy on energy materials

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More